XENE Xenon Pharmaceuticals Inc

$41.16

*Only the 1D chart reflects 15-min delayed quotes during market hours. Other timeframes update after market close.

Reporting for fiscal period ending —
Expected on —
Report Time: Unknown Release Time
The Whisper Number
—
Consensus Estimate: —
Revenue Estimate: —

Latest Earnings Insight

Updated On 11/21/2025

About Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, is dedicated to developing therapies to treat patients with neurological disorders in Canada. The company is headquartered in Burnaby, Canada.

Website: https://www.xenon-pharma.com

Sector
LIFE SCIENCES
Industry
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
Country
USA
Currency
USD
Fiscal Year End
December
CIK
1582313
Address
200 - 3650 GILMORE WAY, BURNABY, BC, CA
Valuation
Market Cap
$2.69B
P/E Ratio
nan
PEG Ratio
-0.06
Price to Book
3.56
Performance
EPS
$-3.01
Dividend Yield
—
Profit Margin
0.00%
ROE
-27.90%
Technicals
50D MA
$35.47
200D MA
$39.39
52W High
$46.00
52W Low
$26.74
Fundamentals
Shares Outstanding
77M
Target Price
$57.31
Beta
1.22

XENE EPS Estimates vs Actual

● Estimated
● Actual

XENE News & Sentiment

Nov 06, 2025 • Benzinga NEUTRAL
Xenon to Present at Upcoming Investor Conferences - Xenon Pharmaceuticals ( NASDAQ:XENE )
VANCOUVER, British Columbia and BOSTON, Nov. 06, 2025 ( GLOBE NEWSWIRE ) -- Xenon Pharmaceuticals Inc. ( NASDAQ:XENE ) , a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need, ...
Nov 04, 2025 • Zacks Commentary NEUTRAL
Xenon Q3 Loss Narrower Than Expected, Pipeline Development in Focus
XENE reports narrower-than-expected Q3 loss as the biotech advances multiple late-stage studies of azetukalner across epilepsy and mood disorders.
Oct 16, 2025 • GlobeNewswire NEUTRAL
Xenon Announces Appointment of Tucker Kelly as Chief Financial Officer
Mr. Kelly is a proven strategic CFO with significant financial, operational and commercialization leadership experience Mr. Kelly is a proven strategic CFO with significant financial, operational and commercialization leadership experience ...
Sep 10, 2025 • Benzinga SOMEWHAT-BULLISH
Design Therapeutics Appoints Justin Gover to Board of Directors - Compass Pathways ( NASDAQ:CMPS ) , Design Therapeutics ( NASDAQ:DSGN )
CARLSBAD, Calif., Sept. 10, 2025 ( GLOBE NEWSWIRE ) -- Design Therapeutics, Inc. DSGN, a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced the appointment of industry veteran Justin Gover to its Board of Directors, effective ...
Sep 10, 2025 • Zacks Commentary NEUTRAL
Why Is Xenon Pharmaceuticals ( XENE ) Up 4.2% Since Last Earnings Report?
Xenon Pharmaceuticals (XENE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Aug 29, 2025 • GlobeNewswire SOMEWHAT-BULLISH
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 )
VANCOUVER, British Columbia and BOSTON, Aug. 29, 2025 ( GLOBE NEWSWIRE ) -- Xenon Pharmaceuticals Inc. ( Nasdaq: XENE ) , a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need, ...
Sentiment Snapshot

Average Sentiment Score:

0.235
50 articles with scored sentiment

Overall Sentiment:

Bullish

XENE Reported Earnings

Aug 11, 2025
Jun 30, 2025 (Pre market)
2.06 Surprise
  • Reported EPS: $1.07
  • Estimate: $-0.99
  • Whisper: —
  • Surprise %: 208.1%
May 12, 2025
Mar 31, 2025 (Pre market)
0.07 Surprise
  • Reported EPS: $-0.83
  • Estimate: $-0.90
  • Whisper: —
  • Surprise %: 7.5%
Feb 27, 2025
Dec 31, 2024 (Pre market)
-0.0 Surprise
  • Reported EPS: $-0.84
  • Estimate: $-0.84
  • Whisper: —
  • Surprise %: -0.1%
Nov 12, 2024
Sep 30, 2024 (Pre market)
0.0 Surprise
  • Reported EPS: $-0.81
  • Estimate: $-0.81
  • Whisper: —
  • Surprise %: 0.0%
Aug 08, 2024
Jun 30, 2024 (Post market)
-0.05 Surprise
  • Reported EPS: $-0.75
  • Estimate: $-0.70
  • Whisper: —
  • Surprise %: -7.1%
May 09, 2024
Mar 31, 2024 (Post market)
0.04 Surprise
  • Reported EPS: $-0.62
  • Estimate: $-0.66
  • Whisper: —
  • Surprise %: 6.1%
Feb 29, 2024
Dec 31, 2023 (Post market)
0.12 Surprise
  • Reported EPS: $-0.64
  • Estimate: $-0.76
  • Whisper: —
  • Surprise %: 15.8%
Nov 08, 2023
Sep 30, 2023 (Post market)
0.04 Surprise
  • Reported EPS: $-0.73
  • Estimate: $-0.77
  • Whisper: —
  • Surprise %: 5.2%
Aug 09, 2023
Jun 30, 2023 (Post market)
-0.02 Surprise
  • Reported EPS: $-0.72
  • Estimate: $-0.70
  • Whisper: —
  • Surprise %: -2.9%

Financials